Aptose Provides Update on APTO-253 Program
20. Dezember 2021 07:30 ET
|
Aptose Biosciences, Inc.
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE)...
Aptose Presents Highlights from ASH and Corporate Update Event
06. Dezember 2020 17:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
Aptose Reports Results for the Third Quarter 2020
10. November 2020 16:01 ET
|
Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
04. November 2020 10:17 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...